SpyGlass Pharma insider entity Vensana Capital I, L.P., through its affiliated general partner, reported multiple transactions in connection with the company’s initial public offering. On February 9, 2026, its holdings of Series B, Series C‑1, Series C‑2 and Series D preferred stock automatically converted into common stock on a one‑for‑5.7329 basis immediately before the IPO, resulting in indirect ownership of 3,145,619 common shares. On the same date, the entity also purchased 165,000 common shares at $16 per share, bringing its total indirect common stock position to 3,310,619 shares, which are held by Vensana Capital I, L.P. The filing notes that Vensana Capital I GP, LLC and its managing directors, including board member Kirk Nielsen and Peter Justin Klein, may be deemed to share voting and investment power, but they disclaim beneficial ownership except to the extent of their pecuniary interests.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Behbahani Ali reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Nielsen Kirk G. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma, Inc. director Zachary Scheiner was granted a stock option covering 27,400 shares of common stock at an exercise price of $16 per share on February 5, 2026. The option vests in equal monthly installments over 36 months, conditioned on his continuing service as an Outside Director.
According to the filing, Scheiner holds this option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Any net cash or stock received upon exercise must be turned over to RA Capital Management, L.P. to offset advisory fees, and Scheiner disclaims beneficial ownership of the option and underlying shares.
Khan Bilal Arshad reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 13,700 shares. Following the reported transactions, holdings were 13,700 shares.
SpyGlass Pharma director Habib J. Dable was granted stock options to acquire 27,400 shares of common stock on February 5, 2026. The options have an exercise price of $16 per share and were awarded as a derivative security grant.
According to the award terms, the options vest over three years, with one thirty-sixth of the shares vesting each month after the grant date, so long as Dable continues to serve as an Outside Director under the company’s 2026 Equity Incentive Plan.
Pardo Geoffrey B reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Dybbs Michael reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma director Elizabeth G. O'Farrell received a stock option grant covering 13,700 shares of common stock on February 5, 2026. The option has an exercise price of $16 per share, expires on February 5, 2036, and was awarded at no cost to her.
The option will vest 100% on the earlier of one year after the grant date or immediately before the next annual meeting of stockholders, provided she continues as an Outside Director. Following this grant, she beneficially owns options for 13,700 shares directly.